BHVN Stock Forecast & Price Target

Biohaven is attractive fundamentally because management has sharpened the business into a leaner, more sustainable model, with the $350M upfront and $50M next year expected to reduce dilution risk and, alongside lower Kv7 spend and no salesforce buildout, potentially fund operations into 2028. The company still retains meaningful upside through a differentiated pipeline spanning neuroscience, immunology, and oncology, especially the degrader platform and BHV-7000, which is viewed as potentially cleaner on safety while the degrader programs are estimated to represent a more than $4B opportunity by 2035. Despite elevated R&D and about $270M in cash, the balance sheet appears manageable into '27, and multiple catalysts in 2H26 and October '26 preserve optionality across late-stage readouts and partnering opportunities.

Biohaven is facing a material fundamental setback after the FDA issued a partial clinical hold on September 4 for opakalim, pausing new enrollment and pushing out program completion despite dosing continuing in more than 600 randomized patients and over 1,200 participants dosed overall. The delay threatens BHV-7000’s competitive position versus Xenon, while the still-pending SK Biopharmaceuticals deal remains a critical but uncertain source of $400M in near-term cash plus up to $150M in milestones and tiered royalties, underscoring Biohaven’s dependence on financing because it generates no revenue. More broadly, the company has no approved assets, several programs face development and differentiation risk, and a failed near-term readout or further pipeline setbacks could pressure the investment case materially.